SLC5A2 and diabetes mellitus: Despite indicating a non-significant short-term impact on diabetic management, the study suggested the safe utilization of SGLT-2 inhibitors in post-transplant diabetes management, potentially addressing metabolic complications and electrolyte abnormalities linked to prolonged immunosuppression [14].